Resilience Receives USD $164 Million Investment from the Government of Canada to Modernize and Expand Its Ontario Biomanufacturing Site, Improving Pandemic Preparedness

  • Posted on: 3 June 2021
  • By: admin001

Safa'a Al-Rais, Chief Operating Officer at Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI), a subsidiary of National Resilience, Inc. (Resilience), discusses the Canadian Government's CAD 199.2 million ($163.8 million) investment in the site, through the Strategic Innovation Fund. The investment will help increase manufacturing capacity for vaccines and therapeutics, including novel technologies such as mRNA that are being used to fight COVID-19. The expansion will build on RBI’s existing strengths as an important biomanufacturing organization in Canada, maintaining 295 existing jobs and create 205 new full-time positions at the Mississauga facility.